NCT06588530

PFAS Exposure and Immune Response to Vaccination in Adults

Effects of Exposure to Per- and Polyfluoroalkyl Substances (PFAS) on Innate and Adaptive Immune Responses to Tetanus-diphtheria (Td) Vaccination Among Adults in a Community-based Panel Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Rutgers, The State University of New Jersey · Academic / Other
• Sex: All
• Age: 18 Years – 89 Years
• Healthy volunteers: Accepted

Summary

This clinical trial aims to investigate how exposure to Perfluorononanoic acid (PFNA), a type of per- and polyfluoroalkyl substance (PFAS), affects the immune response to the standard tetanus and diphtheria (Td) vaccine. The study focuses on participants from a community with known prior PFNA exposure through contaminated drinking water. The main question it aims to answer is: * Does exposure to PFNA weaken the body's initial immune response, leading to lower levels of protective antibodies after vaccination? Participants will: * Receive Tetanus and Diphtheria (Td) booster vaccination * Visit the study office 7 times over a 30-day period * Have blood and saliva collected at each study visit

Conditions

• Innate Inflammatory Response
• Vaccination
• Diphtheria
• Tetanus
• Environmental Exposure
• Vaccine
• Antibodies
• Adult
• Immunity
• Pollution; Exposure

Interventions

Type	Name	Description
BIOLOGICAL	TENIVAC	TENIVAC (Tetanus and Diphtheria Toxoids Adsorbed) is an active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older.

Timeline

• Start date: 2024-11-04
• Primary completion: 2025-01-08
• Completion: 2025-01-08
• First posted: 2024-09-19
• Last updated: 2025-12-30
• Results posted: 2025-12-30

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study